Overview
The primary purpose of this study is to evaluate safety of LEQEMBI in the real-world clinical setting as reported by events of amyloid-related imaging abnormalities (ARIA)-edema (ARIA-E), ARIA-hemosiderin deposition (ARIA-H), symptomatic ARIA-E, symptomatic ARIA-H, and intracerebral hemorrhage (ICH) greater-than 1 centimeter (cm) in patients treated with LEQEMBI.
Eligibility
Inclusion Criteria:
- Enrolled in JOY-ALZ before the decision to treat with LEQEMBI
- The clinical decision to treat with LEQEMBI has already been made
- Provides written informed consent for the use of medical information to be shared with Eisai Korea Inc.
Exclusion Criteria:
- Currently participating in an interventional clinical study


